A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

Stopped Internal decision to progress alternate molecule with more preferable profile

Conditions

• Infections, Bacterial

Interventions

• DRUG: GSK945237
• DRUG: Placebo
• DRUG: Linezolid
• DRUG: Moxifloxacin

Sponsor

GlaxoSmithKline